Karolina joined Parkwalk in 2021, where she leads new investments and manages a portfolio of seed and Series A companies across therapeutics, life science tools and platforms, and digital health. She serves on the boards of several companies, including Ikarovec, Immutrin, Scripta Thx, Enhanc3D Genomics, Semarion, Qkine, and Psyomics, and is a frequent speaker at biotech and investment conferences.
She brings over 15 years of experience in the biotech and life sciences industry, spanning drug discovery, technology transfer, company building, business development, and equity financing. Karolina began her career in the Cambridge biotech ecosystem in 2009 and co-founded the first life sciences startup accelerator in 2018. Prior to joining Parkwalk, she worked in R&D and corporate roles at Arecor, MedImmune/AstraZeneca, and other organisations, contributing to programs in oncology (antibodies/ADCs), diabetes, and neuroscience (peptides).
Karolina holds a PhD in peptide therapeutics and protein folding from the University of Cambridge, where her research focused on GLP-1 and its applications in metabolic science and neuroscience. She also holds an Executive MBA from HEC Paris.
